Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry.

Atrial fibrillation EORP Non-interventional Observational Prospective Registry

Journal

European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796

Informations de publication

Date de publication:
03 05 2021
Historique:
received: 27 05 2020
accepted: 02 06 2020
pubmed: 10 6 2020
medline: 15 12 2021
entrez: 10 6 2020
Statut: ppublish

Résumé

The European Society of Cardiology (ESC) EURObservational Research Programme (EORP)-Atrial Fibrillation (AF) III Registry aims to identify contemporary patterns in AF management in clinical practice, assess their compliance with the 2016 ESC AF Guidelines, identify major gaps in guideline implementation, characterize the clinical practice settings associated with good vs. poor guideline implementation and assess and compare the 1-year outcome of guideline-adherent vs. guideline non-adherent management strategies. Consecutive adult AF patients (n = 8306) were enrolled between 1 July 2018 and 15 July 2019, and individual patient data were prospectively collected across 192 centres and 31 participating countries during the 3-month enrolment period per centre. The Registry collected baseline and 1-year follow-up data in the eight main domains: patient demographic/enrolment setting, AF diagnosis/characterization, diagnostic assessment, stroke prevention treatments, arrhythmia-directed therapies, integrated AF management, major outcomes (death, non-fatal stroke or systemic embolic event, and non-fatal bleeding event), and the quality of life questionnaire. The EORP-AF III Registry is an international, prospective registry of care and outcomes of patients treated for AF, which will provide insights into the contemporary patterns in AF management, ESC AF Guidelines implementation in routine practice and barriers to optimal management of this highly prevalent arrhythmia.

Identifiants

pubmed: 32514547
pii: 5854871
doi: 10.1093/ehjqcco/qcaa050
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

229-237

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Auteurs

Tatjana S Potpara (TS)

School of Medicine, Belgrade University, Dr Subotica 8, 11000 Belgrade, Serbia.
Cardiology Clinic, Clinical Centre of Serbia, Visegradska 26, 11000 Belgrade, Serbia.

Gregory Y H Lip (GYH)

Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.
Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark.

Nikolaos Dagres (N)

Department of Electrophysiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany.

Harry J M G Crijns (HJMG)

Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands.
Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands.

Giuseppe Boriani (G)

University of Modena and Reggio Emilia, Modena, Italy.

Paulus Kirchhof (P)

Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, Medical School, University of Birmingham, Edgbaston, Birmingham, UK.
University Heart and Vascular Center, UKE Hamburg, Hamburg, Germany.
German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Barcelona, Spain.

Elena Arbelo (E)

Department of Cardiology, Cardiovascular Institute, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
Instit d'Investigació August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Irina Savelieva (I)

Division of Cardiac and Vascular Sciences, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.

Radoslaw Lenarczyk (R)

Department of Cardiology, Congenital Heart Disease and Electrotherapy, Silesian Medical University, Silesian Centre for Heart Diseases, Silesian Medical University, 9 Curie-Sklodowskiej St., Zabrze, Poland.

Laurent Fauchier (L)

Service de Cardiologie, Centre Hospitalier Universitaire Trousseauet Faculté de Médecine EA7505, Université de Tours, Tours, France.

Aldo P Maggioni (AP)

EURObservational Research Programme, European Society of Cardiology, 2035 Route des Colles,Biot, 06903 Sophia-Antipolis, France.
Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.

Chris P Gale (CP)

Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH